Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Phase 1 Completed 10 enrolled Tanabe Pharma Corporation Vertex Pharmaceuticals Incorporated · collab

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.

Timeline

Start: 2007-12
Primary completion: 2008-10
Completion: 2008-10

Publications

Results Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kano M, Matsui H, Kumada H. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat. 2012 Feb;19(2):e112-9. doi: 10.1111/j.1365-2893.2011.01514.x. Epub 2011 Oct 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telaprevir	Small molecule	750 mg	Oral

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Summary

Timeline

Publications

Drugs

Indications